GlassScriptPhysician profile
Sadia Saboor
NPI 1831155043
$4,628.22
in general payments reported to CMS, 2019-2025
24 companies · $1,206 in 2025
The $1,206 reported for 2025 was more than what 82% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $608 · 2020: $356 · 2021: $454 · 2022: $345 · 2023: $818 · 2024: $841 · 2025: $1,206.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,851 · Education: $13.60.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,851.19 |
| Education | $13.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $961.23 | 2019-2025 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $483.49 | 2022-2025 | Jardiance |
| Novo Nordisk INC | $436.55 | 2024-2025 | Ozempic, Rivfloza |
| Amgen INC. | $420.60 | 2019-2025 | Tavneos, Parsabiv, Aranesp |
| Akebia Therapeutics INC | $351.90 | 2019-2024 | Auryxia |
| Otsuka America Pharmaceutical, INC. | $306.12 | 2020-2025 | Jynarque, Voyxact |
| Aurinia Pharma U.S., INC. | $297.32 | 2021-2025 | Lupkynis |
| Ardelyx, INC. | $213.88 | 2024-2025 | Xphozah 30 Mg, Ibsrela |
| Vantive US Healthcare LLC | $190.72 | 2025 | Renal - Pd |
| Ani Pharmaceuticals, INC. | $147.34 | 2023-2024 | Purified Cortrophin Gel |
| Calliditas Therapeutics US INC. | $132.78 | 2023-2024 | Tarpeyo |
| Bayer Healthcare Pharmaceuticals INC. | $105.94 | 2021-2022 | |
| Allergan, INC. | $92.89 | 2020 | |
| Fresenius USA Marketing, INC. | $80.12 | 2019-2025 | Velphoro |
| Glaxosmithkline, LLC. | $60.49 | 2021-2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $59.93 | 2025 | Jardiance |
| Scpharmaceuticals INC. | $54.90 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $46.32 | 2024 | |
| Travere Therapeutics, INC. | $40.05 | 2024 | |
| Cagent Vascular INC | $36.00 | 2025 | Serrantor |
| Mallinckrodt Hospital Products INC. | $34.17 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $27.41 | 2020 | |
| Vifor Pharma, INC. | $24.95 | 2021 | |
| Janssen Pharmaceuticals, INC | $23.12 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sadia Saboor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.